tiprankstipranks
Trending News
More News >
Abcellera Biologics, Inc. (ABCL)
:ABCL
Advertisement

AbCellera Biologics (ABCL) Stock Statistics & Valuation Metrics

Compare
1,935 Followers

Total Valuation

AbCellera Biologics has a market cap or net worth of $1.50B. The enterprise value is $1.08B.
Market Cap$1.50B
Enterprise Value$1.08B

Share Statistics

AbCellera Biologics has 298,484,650 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding298,484,650
Owned by Insiders38.47%
Owned by Institutions0.02%

Financial Efficiency

AbCellera Biologics’s return on equity (ROE) is -0.15 and return on invested capital (ROIC) is -19.85%.
Return on Equity (ROE)-0.15
Return on Assets (ROA)-0.12
Return on Invested Capital (ROIC)-19.85%
Return on Capital Employed (ROCE)-0.25
Revenue Per Employee48.38K
Profits Per Employee-273.25K
Employee Count596
Asset Turnover0.02
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.
PE Ratio
PS Ratio0.00
PB Ratio1.15
Price to Fair Value0.82
Price to FCF-8.25
Price to Operating Cash Flow-15.06
PEG Ratio3.91

Income Statement

In the last 12 months, AbCellera Biologics had revenue of 28.83M and earned -162.86M in profits. Earnings per share was -0.55.
Revenue28.83M
Gross Profit-68.17M
Operating Income-314.77M
Pretax Income-200.40M
Net Income-162.86M
EBITDA-204.15M
Earnings Per Share (EPS)-0.55

Cash Flow

In the last 12 months, operating cash flow was -77.89M and capital expenditures -64.58M, giving a free cash flow of -142.47M billion.
Operating Cash Flow-77.89M
Free Cash Flow-142.47M
Free Cash Flow per Share-0.48

Dividends & Yields

AbCellera Biologics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.46
52-Week Price Change53.99%
50-Day Moving Average3.20
200-Day Moving Average2.85
Relative Strength Index (RSI)69.67
Average Volume (3m)7.58M

Important Dates

AbCellera Biologics upcoming earnings date is Aug 7, 2025, After Close (Confirmed).
Last Earnings DateMay 8, 2025
Next Earnings DateAug 7, 2025
Ex-Dividend Date

Financial Position

AbCellera Biologics as a current ratio of 9.81, with Debt / Equity ratio of 6.18%
Current Ratio9.81
Quick Ratio9.81
Debt to Market Cap0.00
Net Debt to EBITDA0.45
Interest Coverage Ratio0.00

Taxes

In the past 12 months, AbCellera Biologics has paid -37.54M in taxes.
Income Tax-37.54M
Effective Tax Rate0.19

Enterprise Valuation

AbCellera Biologics EV to EBITDA ratio is -3.78, with an EV/FCF ratio of -4.13.
EV to Sales26.75
EV to EBITDA-3.78
EV to Free Cash Flow-4.13
EV to Operating Cash Flow-7.11

Balance Sheet

AbCellera Biologics has $605.27M in cash and marketable securities with $63.21M in debt, giving a net cash position of -$542.06M billion.
Cash & Marketable Securities$605.27M
Total Debt$63.21M
Net Cash-$542.06M
Net Cash Per Share-$1.82
Tangible Book Value Per Share$3.28

Margins

Gross margin is -474.21%, with operating margin of -1091.69%, and net profit margin of -564.83%.
Gross Margin-474.21%
Operating Margin-1091.69%
Pretax Margin-695.02%
Net Profit Margin-564.83%
EBITDA Margin-708.04%
EBIT Margin-1044.45%

Analyst Forecast

The average price target for AbCellera Biologics is $7.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$7.67
Price Target Upside52.79% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast-35.41%
EPS Growth Forecast-12.26%

Scores

Smart Score10
AI Score59
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis